Itemaren erregistro erraza erakusten du

MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy

dc.contributor.authorUmerez, Maitane
dc.contributor.authorGutiérrez Camino, Ángela ORCID
dc.contributor.authorMuñoz Maldonado, Carmen
dc.contributor.authorMartín Guerrero, Idoia
dc.contributor.authorGarcía-Orad Carles, África ORCID
dc.date.accessioned2017-05-11T07:57:46Z
dc.date.available2017-05-11T07:57:46Z
dc.date.issued2017-03-27
dc.identifier.citationPharmacogenomics & Personalized Medicine 10 : 69-78 (2017)es_ES
dc.identifier.issn1178-7066
dc.identifier.urihttp://hdl.handle.net/10810/21505
dc.description.abstractMethotrexate (MTX) is an important component in the therapy used to treat childhood acute lymphoblastic leukemia ( ALL). Methylenetetrahydrofolate reductase ( MTHFR) is a key enzyme for MTX pharmacokinetics. Two single-nucleotide polymorphisms in MTHFR gene, C677T and A1298C, affecting MTHFR activity, have been widely studied as potential markers of MTX toxicity and/or outcome in pediatric ALL. In this review, we show that the majority of published reports do not find association or present opposite effect. Therefore, MTHFR C677T and A1298C polymorphisms do not seem to be good markers of MTX-related toxicity and/or outcome in pediatric ALL. The efforts should be focused on other genes, such as transporter genes or microRNA-related genes.es_ES
dc.language.isoenges_ES
dc.publisherDove Medical Presses_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/es/*
dc.subjectMTHFRes_ES
dc.subjecttoxicityes_ES
dc.subjectoutcomees_ES
dc.subjectC677Tes_ES
dc.subjectA1298Ces_ES
dc.subjectmethylenetetrahidrofolate reductase C677Tes_ES
dc.subjectgenetic polymorphismses_ES
dc.subjectcandidate geneses_ES
dc.subjectrisk-factorses_ES
dc.subjectchildrenes_ES
dc.subjecttoxicityes_ES
dc.subjectpharmacogeneticses_ES
dc.subjectassociationes_ES
dc.subjectSLCO1B1es_ES
dc.subjectmetaanalysises_ES
dc.titleMTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder© 2017 Umerez et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.phpes_ES
dc.rights.holderAtribución-NoComercial 3.0 España*
dc.relation.publisherversionhttps://www.dovepress.com/mthfr-polymorphisms-in-childhood-acute-lymphoblastic-leukemia-influenc-peer-reviewed-article-PGPMes_ES
dc.identifier.doi10.2147/PGPM.S107047
dc.departamentoesGenética, antropología física y fisiología animales_ES
dc.departamentoeuGenetika,antropologia fisikoa eta animalien fisiologiaes_ES
dc.subject.categoriaMOLECULAR MEDICINE
dc.subject.categoriaPHARMACOLOGY AND PHARMACY


Item honetako fitxategiak

Thumbnail
Izena:
license_rdf
Tamaina:
920bytes
Formatua:
application/rdf+xml
Ikusi/Ireki
Thumbnail
Izena:
PGPM-107047-mthfr-polymorphism ...
Tamaina:
430.7Kb
Formatua:
PDF
Deskribap:
Artículo principal
Ikusi/Ireki

Item hau honako bilduma honetan/hauetan agertzen da

Itemaren erregistro erraza erakusten du

© 2017 Umerez et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php
Bestelakorik adierazi ezean, itemaren baimena horrela deskribatzen da:© 2017 Umerez et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php